CA24477V1058
CA24477V1058
Definium Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 90/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±86.3% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 2.2x as much as the broader market.
Beta (Market Relation)
2.19x
Above averageVolatility (5Y p.a.)
86.3% p.a.
5-Year HorizonMax Drawdown (5Y)
-95.0%
5-Year HorizonSharpe Ratio
-0.02
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +166.8% |
| 3 Years | 83.3% | -58.4% | 1.48 | +125.8% |
| 5 Years | 86.3% | -95.0% | -0.02 | +0.3% |
| 10 Years | 1515.5% | -99.9% | 0.02 | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
High market risk: Beta of 2.19 indicates above-average volatility compared to the broader market.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (86.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -99.9% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
4 ISS Score: 4 / 10
Audit Risk
7 ISS Score: 7 / 10
Board Risk
3 ISS Score: 3 / 10
Short Ratio
5.76